Lieyun.com Beijing reported on February 10 that Lieyun.com recently learned that Cati Medical, a biotechnology company specializing in tumor infiltrating lymphocyte therapy (TIL) therapy, announced the completion of a 100 million yuan Pre-B round of financing, led by Fenglin Capital.
.
It is understood that this round of financing will be used to support Cati Medical’s “Super TIL” cell therapy product in completing the IND application.
Previously, Cati Medical had received Series A+ investment from investment institutions such as China Construction Bank Medical Growth Fund.
Immunotherapy has become a general trend in tumor treatment.
Although CAR-T therapy shines in the field of hematological tumors, it is often ineffective for solid tumors, which account for more than 90% of cancer patients. This is mainly due to the heterogeneity and microenvironmental characteristics of solid tumors.
Tumor-infiltrating lymphocyte (TIL) therapy is the best solution to solve the problem of tumor heterogeneity and is considered a new hope for conquering solid tumors.
The TIL therapy of the American company Iovance has received breakthrough therapy designation from the US FDA, which means that TIL is expected to become a new generation of cell therapy drugs after CAR-T.
However, current TIL therapy still faces many difficulties in the tumor microenvironment, cell expansion process, preparation cycle and cost, and TIL therapy also has its natural limitations - it must rely on surgical tissue to obtain cell raw materials, and for most
This is often difficult to do in advanced patients.
Tianyancha APP information shows that Beijing Kati Medical Technology Co., Ltd. was established in June 2015, and its legal representative is Gu Weiyue.
Cati Medical's core R&D team is composed of top scientists and clinical research experts in the industry, and has been deeply involved in innovative immune cell therapy technologies such as TIL/neoantigens for many years.
The "Super TIL" immune cell therapy technology independently developed by Cati Medical is a major upgrade based on the internationally cutting-edge TIL and CAR-T technologies - its products rely on "enhanced receptors" and
Patented technologies such as "amplification factors" can genetically modify TIL cells, comprehensively solving many of the above-mentioned problems regarding the heterogeneity and microenvironment of solid tumors, as well as cell amplification processes, preparation cycles and costs.
In addition, the fourth-generation product developed by Cati Medical - "Super cTIL" only needs to collect TIL cells from peripheral blood, breaking through the limitations of traditional TIL therapy that relies on surgical tissue sampling.
This breakthrough makes TIL therapy almost accessible to everyone, greatly expanding the applicable population.
It is reported that Beijing Cati Medical Company is the only company in China that has human clinical research data on innovative TIL therapies.
The company's early proof-of-concept (POC) clinical study data of "super-potent TIL" in the treatment of advanced solid tumors refractory to traditional treatments has shown exciting results.
In addition, currently, super-potent TILs led by well-known researchers such as Professor Li Jin from Shanghai Oriental Hospital, Professor Guo Jun from Beijing Cancer Hospital, Professor Zhao Haitao from Peking Union Medical College Hospital, and Professor Zhang Yi from the First Affiliated Hospital of Zhengzhou University are being used for different solid tumor indications.
A new round of clinical research is underway, even regardless of cancer types.
Beijing Fenglin Investment Co., Ltd. (referred to as "Fenglin Capital") takes "focusing on value-added services and committing to long-term win-win" as its corporate strategy, and is committed to becoming the "most professional and trustworthy" emerging boutique private equity investment institution.
Help the invested companies continue to grow healthily and strive to create excellent returns for investors.
The core members of Fenglin Capital come from well-known financial investment institutions and technology companies such as Deutsche Bank, CITIC Securities, Bank of Communications, Jinshi Investment, Jiuding Investment, IBM, China Science and Technology Software, etc. The average investment experience of the team is more than 10 years, and the cumulative assets under management have been
Nearly 100 billion yuan, rich investment experience, broad channel resources, and excellent historical performance.
CCB Medical Growth Fund is a market-oriented venture capital fund operated by CCB International that focuses on investment in growth-stage medical companies.
The fund is led by China Construction Bank International and co-initiated and established by high-quality institutions such as Kunming High-tech Group. The first-phase scale is RMB 500 million.
The fund leverages the comprehensive advantages of CCB International’s extensive project sources, investment banking business linkage, and professional investment team in the medical and health industry. It combines the high-quality medical and health industry resources of fund investors to accurately screen technology industrialization projects in the medical and health industry and accelerate the cultivation of innovation.
technology enterprise.
Relying on its rich investment and management experience and deep industry resources, the fund provides comprehensive post-investment value-added services for invested projects, and is committed to growing together with enterprises and investors.
CCB Medical Fund is a series of equity investment funds established by CCB International to deploy the medical and health industry in China. The funds under management include CCB Medical Fund Phase I, CCB Medical Growth Fund, CCB Medical Fund, etc.